JPWO2021045969A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021045969A5
JPWO2021045969A5 JP2022513077A JP2022513077A JPWO2021045969A5 JP WO2021045969 A5 JPWO2021045969 A5 JP WO2021045969A5 JP 2022513077 A JP2022513077 A JP 2022513077A JP 2022513077 A JP2022513077 A JP 2022513077A JP WO2021045969 A5 JPWO2021045969 A5 JP WO2021045969A5
Authority
JP
Japan
Prior art keywords
seq
vaccine
amino acid
hbv
inventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545530A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048411 external-priority patent/WO2021045969A1/en
Publication of JP2022545530A publication Critical patent/JP2022545530A/ja
Publication of JPWO2021045969A5 publication Critical patent/JPWO2021045969A5/ja
Pending legal-status Critical Current

Links

JP2022513077A 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン Pending JP2022545530A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893546P 2019-08-29 2019-08-29
US62/893,546 2019-08-29
US201962941125P 2019-11-27 2019-11-27
US62/941,125 2019-11-27
PCT/US2020/048411 WO2021045969A1 (en) 2019-08-29 2020-08-28 Hepatitis b virus vaccines

Publications (2)

Publication Number Publication Date
JP2022545530A JP2022545530A (ja) 2022-10-27
JPWO2021045969A5 true JPWO2021045969A5 (ko) 2023-08-22

Family

ID=74096044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513077A Pending JP2022545530A (ja) 2019-08-29 2020-08-28 Ｂ型肝炎ウイルスワクチン

Country Status (11)

Country Link
US (1) US20220288195A1 (ko)
EP (1) EP4021923A1 (ko)
JP (1) JP2022545530A (ko)
KR (1) KR20220090497A (ko)
CN (1) CN114729010A (ko)
AU (1) AU2020342385A1 (ko)
BR (1) BR112022003474A2 (ko)
CA (1) CA3149415A1 (ko)
IL (1) IL290924A (ko)
MX (1) MX2022002270A (ko)
WO (1) WO2021045969A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458975A2 (en) 2019-09-30 2024-11-06 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511075A (ja) * 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
PT1294893E (pt) * 2000-06-22 2006-08-31 Ucb Pharma Ltd Modificacao do antigenio nuclear de hepatite b
KR100587944B1 (ko) * 2001-05-25 2006-06-08 (주)두비엘 보강제 및 ＨＢＶ 백신 성분인 Ｂ형 간염 바이러스의ｐｒｅ Ｓ단백질
AU2004285983B2 (en) * 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
TWI555531B (zh) * 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
KR101418836B1 (ko) * 2012-04-05 2014-08-13 서울대학교산학협력단 간질환 진단용 마커 및 이의 용도
EP3473723A1 (en) 2013-03-05 2019-04-24 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
BR112018013387A2 (pt) * 2016-01-12 2019-03-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit

Similar Documents

Publication Publication Date Title
Huang et al. Molecular cloning and sequencing of the Mexico isolate of hepatitis E virus (HEV)
Lagging et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein
Michel et al. Hepatitis B vaccines: protective efficacy and therapeutic potential
EP0522030B1 (en) Hepatitis b vaccine
EP1523557A2 (en) Antigens encoded by alternative reading frame from pathogenic viruses
RU2014104360A (ru) Мутантные полимеразы вируса гепатита в
JP2014527404A5 (ko)
WO2009022236A2 (en) Immunogen platform
JP2003508409A (ja) 慢性ウイルス感染に対するペプチド混合物及びワクチン
CN101057975B (zh) 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用
JPWO2021045969A5 (ko)
JP2003514576A5 (ko)
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
Lacombe et al. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
US5851823A (en) Hepatitis B vaccine
Goodarzi et al. Phylogenetic analysis of HBV based on PreS region in Iranian hepatocellular carcinoma patients
AU701747B2 (en) Hepatitis virus vaccines
CN104130316B (zh) 乙型肝炎病毒表面l蛋白相关肽
Björnsdottir et al. Changing prevalence of hepatitis B virus genotypes in Iceland
WO2020149615A1 (ko) B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
KR0120928B1 (ko) 한국에서 분리한 신규한 c형 바이러스 유전자
AU642729C (en) Hepatitis B vaccine
Wirth et al. Hepatitis B virus mutants in HBsAg positive children
Girard Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
US5989865A (en) Hepatitis B vaccine